

VALUE OF IMMUNOHISTOCHEMICAL EXPRESSION OF P16^{INK4A} IN VARIOUS FORMS OF CERVICAL NEOPLASIA

Essay

*Thesis Submitted in partial fulfillment of the Requirements
of Master Degree in histopathology*

By

Sufyan Ahmed Mukhtar Younes

(M.B.B.Ch)

Faculty of Medicine - Ain Shams University

Under Supervision of

Prof. Dr. Magda Hassan Nasreldin

Professor of Pathology -Faculty of Medicine- Ain Shams University

Prof. Dr.Hala Sobhy Cousha

Professor of Pathology -Faculty of Medicine- Ain Shams University

Dr. Lobna Sadek Amin Shash

Lecturer of Pathology - Faculty of Medicine- Ain Shams University

Faculty of Medicine

Ain Shams

2016



Aknowledgement

*I would like to express my deepest gratitude and appreciation to **Prof. Dr. Magda Hassan Nasreldin** for her wise guidance, valuable and close supervision.*

*I am deeply grateful and thankful to **Prof. Dr.Hala Sobhy Cousha** for her cooperation and support to accomplish this work*

*I like to thank **Dr.Lobna Sadek Amin Shash** for her constant encouragement and motivation that helped me throughout this work*

I shouldn't miss the chance to thank all Staff members of the Early Cancer Detection Unit, Ain Shams Maternity Hospital Faculty of medicine, Ain Shams University for the help and facilities they offered during the course of this study

Finally, I would like to thank my mother and my family for their care and endless support in every step of my life.



List of Contents

Title	Page No.
List of abbreviations	i
List of diagrams	ii
List of figures.....	iii
List of graphs.....	vi
List of tables	vii
Introduction	1
Aim of the study	5
Literature review	
Cervical neoplasia.....	6
- Anatomy of the uterine cervix.....	6
- Histology of the uterine cervix.....	7
- The transformation zone	8
- Tumors of the uterine cervix.....	10
- Histopathology of cervical cancer	13
- Histopathology of cervical intraepithelial lesions	16
- Epidemiology	17
- Risk factors	20
- Clinical presentation of Cancer Cervix	23
- Screening of cervical cancer	23
- Staging & grading of cervical cancer	25
- Types of endometrial cancer	29

List Of Contents

P16 INK4A	31
- Role of p 16 in cell cycle regulation.....	33
- Role of p16 in tumor suppression	40
- Role of p 16 in cell differentiation	41
- Role of p16 in inhibition of tumor invasion and angiogenesis	42
- P 16 expression in cervical neoplasms	44
Material and methods	48
Results.....	57
Discussion	85
Summary and conclusion.....	98
References.....	102
Arabic Summary	

List of Abbreviations

Abb.	Full term
ANOVA	Analysis of variance test
CIN	Cervical intraepithelial neoplasia
DAB	Diaminobenzidine
ECRC	endometrial carcinoma reaching to the cervix
ICSC	invasive cervical squamous cell carcinoma
IECC	invasive endocervical carcinoma
HGSIL	high grade squamous intraepithelial lesions
LGSIL	low grade squamous intraepithelial lesions
PBS	phosphate buffer solution
SIL	Squamous intraepithelial lesion
TBS	Tris buffer saline

List of Diagram

Diagram No.	Title	Page No.
Diagram (1):	Cell types at the transformation zone of the cervix	8
Diagram (2):	Gross anatomy of the uterine cervix	9
Diagram (3)	Cervix cancer morbidity in selected countries since 2001 for 2004 year.	18
Diagram (4):	Cervical cancer stages	28
Diagram (5):	P16 _{CDK4/6} _pRb pathway. Arrows and minus signs represent positive and negative regulatory effects, respectively. P denotes phosphorylated ..	34
Diagram (6):	The mammalian cell cycle.....	37
Diagram (7):	P16 ^{INK4A} inhibits cyclin-dependent kinases (CDKs) 4 and 6.....	38
Diagram (8):	Functions and interactions of the proteins coded by the INK4a/ARF	39
Diagram (9):	Multiple functions of the p16 tumor suppressor..	43

List of Figures

Figure No.	Title	Page No.
Figure (1):	HGSIL of cervix - No invasion (H&Ex100)	69
Figure (2):	HGSIL showing strong p16 cytoplasmic expression in both surface epithelium and the crypt involved with HGSIL at black arrow.....	69
Figure (3):	HSIL with koilocytic changes- Black arrow (H&Ex400).....	70
Figure (4):	HSIL showing strong cytoplasmic p16 expression ..	70
Figure (5):	LSIL of ectocervix showing kolilocytic changes of HPV-black arrow (H&Ex200)	71
Figure (6):	LSIL showing weak p16 cytoplasmic expression (IHCx200)	71
Figure (7):	Poorly differentiated Invasive cervical squamous cell carcinoma (ICSC) (H&Ex200).....	72
Figure (8):	Poorly differentiated ICSC showing strong p16 combined nuclear and cytoplasmic expression (IHCx 200)	72
Figure (9):	Moderately Differentiated Endocervical Adenocarcinoma with clear cell change (H&Ex200).....	73
Figure (10):	Moderately differentiated IECC with prominent clear cell change showing strong p16 combined nuclear & cytoplasmic expression (IHCx100)	73

List Of Figures	
Figure (11):	Invasive keratinizing squamous cell carcinoma (ICSC)74
Figure (12):	ICSC showing strong p16 cytoplasmic expression .74
Figure (13):	Invasive keratinizing cervical squamous cell carcinoma (ICSC) (H&Ex100).....75
Figure (14):	ICSC showing strong p16 combined nuclear and cytoplasmic expression (IHCx100).....75
Figure (15):	(ICSC) with pseudoglandular pattern (H&Ex40).....76
Figure (16):	ICSC with pseudoglandular pattern showing strong p16 cytoplasmic expression (IHCx40).....76
Figure (17):	Invasive poorly differentiated squamous cell carcinoma (ICSC) with nearby native bland endocervical gland-black arrow.....77
Figure (18):	Positive cytoplasmic p16 moderate expression in tumor cells of the previous case ,sparing nearby native bland endocervical gland – black arrow (IHCx100)77
Figure (19):	Invasive cervical squamous cell carcinoma (ICSC) with lymphovascular invasion (H&Ex400)78
Figure (20):	ICSC with lymphovascular invasion showing strong cytoplasmic p16 expression (H&Ex400)78
Figure (21):	Invasive endocervical adenocarcinoma (IECC) (H&Ex200)79
Figure (22):	Positive moderate cytoplasmic p16 expression of the previous case. (IHCx400).....79
Figure (23):	Endometrial adenocarcinoma reaching the cervix (ECRC).....80
Figure (24):	ECRC showing negative p16 expression (IHCx200) 80

List Of Figures	
Figure (25):	Moderately differentiated endocervical adenocarcinoma (IECC) (H&E x 200).....81
Figure (26):	Positive strong expression of p16 showing combined nuclear and cytoplasmic stain of the previous case. (IHCx200)81
Figure (27):	Poorly differentiated invasive endocervical carcinoma (IECC). (H&E x 400).....82
Figure (28):	IECC showing strong predominantly cytoplasmic p16 expression. (IHCx400).....82
Figure (29):	Well differentiated endocervical adenocarcinoma (IECC).....83
Figure (30):	Well differentiated IECC showing strong p16 expression.....83
Figure (31):	Poorly differentiated endometrial adenocarcinoma (ECRC) dissecting myometrial fibers. (H&E x 200).....84
Figure(32):	ECRC dissecting myometrial fibers showing strong combined nuclear and cytoplasmic p16 expression. (IHCx 200)84

List of Graphs

Graph No.	Title	Page No.
Graph (1):	Parity status in study groups	59
Graph (2):	Comparison between study groups as regards p16 expression score	61
Graph (3):	Comparison between study groups as regard P16 results.....	62
Graph (4):	P16 expression in cervical versus endometrial carcinoma.....	63
Graph (5):	P16 expression in cervical intra epithelial squamous lesions versus invasive squamous cell carcinoma.....	64
Graph (6):	P16 expression in (Cervical intra-epithelial lesion and invasive cervical squamous carcinoma) versus endocervical adenocarcinoma tumours	65
Graph (7):	P16 localization in cervical neoplasia (intra-epithelia & invasive) and endometrial carcinoma.....	67
Graph (8):	P16 localization in (Low grade squamous intra-epithelial lesion & high grade squamous intraepithelial) and invasive squamous carcinoma	67
Graph (9):	P16 localization in squamous neoplasia (intra-epithelia& invasive) and adenocarcinoma of cervix	68

List of Tables

Table No.	Title	Page No.
Table (1):	Screening guidelines for cervical cancer.....	25
Table (2):	FIGO staging for cervical cancer	27
Table (3):	Characteristics of type 1 and type II endometrial cancers	30
Table (4):	Classification of cervical intraepithelial neoplasia / Squamous intraepithelial lesion (CIN/SIL).....	50
Table (5):	Comparison between study groups as regard age, parity and HPV infection.....	59
Table (6):	Comparison between study groups as regard the chief complaint:.....	60
Table (7):	Summarized data of recorded scores of the studied cases.....	64
Table (8):	Relation between type of lesion and localization of the marker:	66

Abstract

Title: Value of immunohistochemical expression of P16 INK4A in various form of cervical neoplasia

Background: Cervical carcinoma represents a major public health problem particularly in developing countries with an age adjusted cancer mortality rate up to 10/10 000. HPV is detected in 99% of cervical tumors. P16 diffuse immunohistochemical expression has been established as a surrogate marker for high risk HPV strains identification. Squamous cell carcinoma accounts for 70-80% of cancer cervix whereas, adenocarcinoma accounts for 10-15%. Cervical intraepithelial neoplasia/ lesions (CIN/CIL) are considered risk factors for cancer cervix. Whilst HGSIL represent an absolute precursor lesion, LSIL only progresses to cancer in 10-15% of cases. The trend of progress to cancer still represents a zone of ambiguity especially among LSIL. Another zone of confusion in diagnosing cervical carcinoma is its putative morphological overlap with endometrial adenocarcinoma, a pitfall that has important management consequences.

Aim: The aim of this study is to evaluate the possible role of immunohistochemical expression of p16INK4A in improving the diagnostic performance of different grades of cervical neoplasia (cervical intraepithelial neoplasia and cervical carcinomas). Further, correlation between p16INK4A expression will be done with the various clinicopathologic parameters.

Materials and methods: Immunohistochemical expression of P16INK4A was investigated in 42 cases of cervical neoplasia. These included 7 cases of LGSIL, 4 cases of HGSIL, 17 cases of cervical squamous cell carcinoma, 5 cases of endocervical carcinoma and 9 cases of endometrial carcinoma reaching to the cervix. Semi quantitative assessment using a combined (intensity/percentage) score was interpreted to evaluate expression. Statistical correlation of immunohistochemical results to medical data and microscopic diagnosis was done.

Results: P16INK4A expression showed a highly significant difference between groups as regard overall score with highest score among HGSIL cases (10.5 ± 3.0) and lowest among Endometrial Carcinoma (3.1 ± 3.48),

(P value 0.002) . Also, there was a highly significant difference between groups as regard overall marker result (P value 0.009).Moreover, upon comparing lesions of cervical origin to endometrial carcinomas there was a highly significant difference between the two groups as regard overall score (P value 0.002) and marker result (P value 0.003) with higher score and more positive results among lesions of cervical origin. There was no significant statistical correlation between age or parity of patients and P16INK4A expression.

Conclusion: P16INK4A is a useful conjunction prognostic marker in CIL lesions refining morphological detection of high risk groups. Furthermore, it offers additional diagnostic benefit in verifying cervical origin of adenocarcinoma extending to the endometrium when the clinical/microscopic evaluation is non conclusive.

INTRODUCTION

Cervical cancer has been the main cause for cancer related morbidity and mortality for females worldwide, accounting for 6% of all malignancies in women. About 470,000 new cases are diagnosed annually with nearly 230,000 related deaths **(Parkin et al, 2001)**. It is estimated that it occurs in 0.0015-0.012 % of all pregnancies **(Morimura et al, 2002)**. Moreover 3% of newly diagnosed cervical cancers occurs in pregnant women **(Mcintyre-Seltman and Lesnock, 2008)**.

Although several factors that contribute to cancer cervix development have been identified—mainly intrinsic factors (genetic), and extrinsic factors belonging to the Human Papillomavirus (HPV)—genetic factors show great potential for use as susceptibility or prognosis factors **(Torres-Poveda et al, 2016, Audirac-Chalifour et al, 2016)**.

Low-grade cervical intraepithelial neoplasia LSIL may progress to high-grade HSIL. However, both mild and moderate cervical dysplasias are more likely to regress than to progress. **Howaty et al, (1999)** estimated the risk of mild dysplasia progressing to cancer as 1% per year, and that of

moderate dysplasia as 16% within 2 years and 25% within 5 years.

Trimble et al (2005) reported that CIN2/3 lesions associated with human papilloma virus HPV16 are significantly less likely to resolve spontaneously than those caused by other types of HPV.

The direct precursor of cervical cancer is represented by Cervical Intraepithelial Neoplasia (CIN) that is usually detected and managed through the Papanicolaou (Pap) test cytological screening and/or high risk Human Papillomavirus DNA testing (**Trimble et al, 2005**).

Etiological role of papilloma viruses in cervical cancer is established while its role in cellular gene alterations along the course of tumor progression is less clear (**Karcheva et al, 2007**). The conceptual advances and development of an effective vaccine in the past twenty-five years have made it possible to envision a long-term reduction in mortality and morbidity for HPV related tumors of the lower female genital tract (**Wigle et al, 2013**).

Tumour suppressor genes code for proteins that restrict the proliferative and survival capacity of a cell. Such genes may be rendered dysfunctional through multiple mechanisms